The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Triple negative breast cancer: A thorough review of biomarkers
Abstract
Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The tumorigenesis is not likely to be driven by hormonal or HER2 pathway. In comparison to other types of breast cancer, TNBC stands out for its aggressive behavior, more prone to early recurrence. Historically, TNBC has been considered a disease with poor response to molecular target therapy, requiring better validation of biomarkers. Recent issues related to tumor heterogeneity have been widely discussed suggesting the subdivision of TNBC into different molecular subtypes. Through a complete research on the main published trials databases and platforms of ongoing clinical studies, the current manuscript was carried out in order to present a critical view of the role of immunohistochemical and molecular biomarkers for the prognosis and response prediction of TNBC to traditional therapy and new molecular target agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids
Srinivasan, M., Sedmak, D., & Jewell, S. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64472-0 · Cited by 1,318
Adams, S., Gray, R. J., Demaria, S., Goldstein, L., Perez, E. A., Shulman, L. N., Martino, S., Wang, M., Jones, V. E., Saphner, T. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.55.0491 · Cited by 1,299
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., van Leeuwen, F. E., Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., Blomqvist, C., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000279 · Cited by 1,116
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897
Repair of Strand Breaks by Homologous Recombination
Jasin, M., & Rothstein, R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012740 · Cited by 887
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
Schmidt, M., Böhm, D., von Törne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kölbl, H., & Gehrmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5206 · Cited by 836
Abkevich, V, Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith-McCune, K., Broaddus, R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 815
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
Holmes, D. I. R., & Zachary, I. C. (2005) · Genome biology · doi:10.1186/gb-2005-6-2-209 · Cited by 778
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
DeNardo, D. G., & Coussens, L. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1746 · Cited by 677
Couch, F. J., Hart, S. N., Sharma, P., Toland, A. E., Wang, X., Miron, P., Olson, J. E., Godwin, A. K., Pankratz, V. S., Olswold, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1414 · Cited by 672
Popova, T., Manié, E., Rieunier, G., Caux-Moncoutier, V., Tirapo, C., Dubois, T., Delattre, O., Sigal-Zafrani, B., Bollet, M., Longy, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1470 · Cited by 665
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 661
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer
Lin, A., Li, C., Xing, Z., Hu, Q., Liang, K., Han, L., Wang, C., Hawke, D. H., Wang, S., Zhang, Y., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3295 · Cited by 565
van de Rijn, M., Perou, C. M., Tibshirani, R., Haas, P., Kallioniemi, O., Kononen, J., Torhorst, J., Sauter, G., Zuber, M., Köchli, O. R., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64476-8 · Cited by 560
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, I. M., & Kurman, R. J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.85 · Cited by 513
Prognostic and predictive value of PDL1 expression in breast cancer
Sabatier, R., Finetti, P., Mamessier, E., Adelaide, J., Chaffanet, M., Ali, H. R., Viens, P., Caldas, C., Birnbaum, D., & Bertucci, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3216 · Cited by 508
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Tan, D. S. P., Rothermundt, C., Thomas, K., Bancroft, E., Eeles, R., Shanley, S., Ardern-Jones, A., Norman, A., Kaye, S. B., & Gore, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1703 · Cited by 469
Dieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404913 · Cited by 453
Schalper, K. A., Velcheti, V., Carvajal, D., Wimberly, H., Brown, J., Pusztai, L., & Rimm, D. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2702 · Cited by 450
Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascón, P., Guillém, V., González, S., Sauleda, S., Marimón, I., Tabernero, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.326 · Cited by 411
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Niemeier, L. A., Dabbs, D. J., Beriwal, S., Striebel, J. M., & Bhargava, R. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.159 · Cited by 401
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
Lund, M. J., Trivers, K. F., Porter, P. L., Coates, R. J., Leyland-Jones, B., Brawley, O. W., Flagg, E. W., O’Regan, R. M., Gabram, S. G. A., & Eley, J. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9926-3 · Cited by 390
Augoff, K., McCue, B., Plow, E. F., & Sossey-Alaoui, K. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-5 · Cited by 363
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Expression of androgen receptors in primary breast cancer
Park, S., Koo, J., Park, H. S., Kim, J.-H., Choi, S.-Y., Lee, J. H., Park, B.-W., & Lee, K. S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp510 · Cited by 343
Targeting the PI3-kinase pathway in triple-negative breast cancer
Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 333
High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
Park, H. S., Jang, M. H., Kim, E. J., Kim, H. J., Lee, H. J., Kim, Y. J., Kim, J. H., Kang, E., Kim, S.-W., Kim, I. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.251 · Cited by 300
van Schooneveld, E., Wildiers, H., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0526-y · Cited by 296
Gerwins, P., Sköldenberg, E., & Claesson-Welsh, L. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00062-7 · Cited by 290
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 289
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 286
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Cristofanilli, M., Pierga, J.-Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.004 · Cited by 274
lincRNA-RoR and miR-145 Regulate Invasion in Triple-Negative Breast Cancer via Targeting ARF6
Eades, G., Wolfson, B., Zhang, Y., Li, Q., Yao, Y., & Zhou, Q. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0251 · Cited by 271
Targeting the Phosphoinositide-3 (PI3) Kinase Pathway in Breast Cancer
Baselga, J. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-12 · Cited by 261
Viale, G., On the behalf of the International Breast Cancer Study Group, Regan, M. M., On the behalf of the International Breast Cancer Study Group, Mastropasqua, M. G., On the behalf of the International Breast Cancer Study Group, Maffini, F., On the behalf of the International Breast Cancer Study Group, Maiorano, E., On the behalf of the International Breast Cancer Study Group, et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm289 · Cited by 247
A review of PARP inhibitors: from bench to bedside
Underhill, C., Toulmonde, M., & Bonnefoi, H. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq322 · Cited by 240
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., Timms, K., Abkevich, V., Schackmann, E. A., Wapnir, I. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0085 · Cited by 233
Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., et al. (2016) · Histopathology · doi:10.1111/his.12904 · Cited by 231
Mao, Y., Qu, Q., Zhang, Y., Liu, J., Chen, X., & Shen, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115103 · Cited by 218
Riva, F., Bidard, F.-C., Houy, A., Saliou, A., Madic, J., Rampanou, A., Hego, C., Milder, M., Cottu, P., Sablin, M.-P., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.262337 · Cited by 213
Sharma, P., Klemp, J. R., Kimler, B. F., Mahnken, J. D., Geier, L. J., Khan, Q. J., Elia, M., Connor, C. S., McGinness, M. K., Mammen, J. M. W., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2980-0 · Cited by 201
Stirzaker, C., Zotenko, E., Song, J. Z., Qu, W., Nair, S. S., Locke, W. J., Stone, A., Armstong, N. J., Robinson, M. D., Dobrovic, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms6899 · Cited by 190
Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis
Matouk, I. J., Abbasi, I., Hochberg, A., Galun, E., Dweik, H., & Akkawi, M. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e328306a3a2 · Cited by 190
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer
Adams, B. D., Wali, V. B., Cheng, C. J., Inukai, S., Booth, C. J., Agarwal, S., Rimm, D. L., Győrffy, B., Santarpia, L., Pusztai, L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2321 · Cited by 174
He, J., Peng, R., Yuan, Z., Wang, S., Peng, J., Lin, G., Jiang, X., & Qin, T. (2012) · Medical Oncology · doi:10.1007/s12032-011-9832-0 · Cited by 170
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
Ribatti, D., Nico, B., Ruggieri, S., Tamma, R., Simone, G., & Mangia, A. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.07.002 · Cited by 166
DNA methylation based biomarkers: Practical considerations and applications
How Kit, A., Nielsen, H. M., & Tost, J. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.014 · Cited by 162
Madic, J., Kiialainen, A., Bidard, F., Birzele, F., Ramey, G., Leroy, Q., Frio, T. R., Vaucher, I., Raynal, V., Bernard, V., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29265 · Cited by 160
MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
Kahraman, M., Röske, A., Laufer, T., Fehlmann, T., Backes, C., Kern, F., Kohlhaas, J., Schrörs, H., Saiz, A., Zabler, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-29917-2 · Cited by 158
Telli, M. L., Hellyer, J. A., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., Gutin, A., Abkevich, V., Peterson, R. N., Neff, C. D., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4624-7 · Cited by 138
Targeting triple negative breast cancer: Is p53 the answer?
Turner, N. H., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L., D’Incalci, M., Piccolo, S., Veronesi, A., Zambelli, A., Sal, G. D., et al. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.001 · Cited by 135
Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
Wang, C., Pan, B., Zhu, H., Zhou, Y., Mao, F., Lin, Y., Xu, Q., & Sun, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.10208 · Cited by 132
Chen, Y.-H., Hancock, B. A., Solzak, J. P., Brinza, D., Scafe, C., Miller, K. D., & Radovich, M. (2017) · npj Breast Cancer · doi:10.1038/s41523-017-0028-4 · Cited by 129
Qu, Q., Mao, Y., Fei, X., & Shen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082650 · Cited by 127
Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 124
Schmid, P., Cruz, C., Braiteh, F. S., Eder, J. P., Tolaney, S. M., Kuter, I., Nanda, R., Chung, C. T., Cassier, P. A., Delord, J., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-2986 · Cited by 119
Zhao, Z., Chen, C., Liu, Y., & Wu, C. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.006 · Cited by 114
Liu, D., He, J., Yuan, Z., Wang, S., Peng, R., Shi, Y., Teng, X., & Qin, T. (2011) · Medical Oncology · doi:10.1007/s12032-011-9827-x · Cited by 109
Thike, A. A., Iqbal, J., Cheok, P. Y., Chong, A. P. Y., Tse, G. M.-K., Tan, B. K. T., Tan, P. B. O., Wong, N. S., & Tan, P. H. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181e02f45 · Cited by 109
Immune cell quantitation in normal breast tissue lobules with and without lobulitis
Degnim, A. C., Brahmbhatt, R. D., Radisky, D. C., Hoskin, T. L., Stallings‐Mann, M. L., Laudenschlager, M., Mansfield, A. S., Frost, M. H., Murphy, L., Knutson, K. L., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2896-8 · Cited by 107
MicroRNA-34 family in breast cancer: from research to therapeutic potential
İmani, S., Wu, R., & Fu, J. (2018) · Journal of Cancer · doi:10.7150/jca.25576 · Cited by 104
Targeting the androgen receptor in triple-negative breast cancer
Gucalp, A., & Traina, T. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.004 · Cited by 98
Gasparini, P., Fassan, M., Cascione, L., Güler, G., Balcı, S., Irkkan, Ç., Paisie, C. A., Lovat, F., Morris, Q., Zhang, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088525 · Cited by 92
Exploring specific prognostic biomarkers in triple-negative breast cancer
Bao, C., Lu, Y., Chen, J., Chen, D., Lou, W., Ding, B., Xu, L., & Fan, W. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2043-x · Cited by 92
MicroRNAs in the prognosis of triple-negative breast cancer
Lü, L., Mao, X., Shi, P., He, B., Xu, K., Zhang, S., & Wang, J. (2017) · Medicine · doi:10.1097/md.0000000000007085 · Cited by 86
Asano, Y., Kashiwagi, S., Onoda, N., Kurata, K., Morisaki, T., Noda, S., Takashima, T., Ohsawa, M., Kitagawa, S., & Hirakawa, K. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.434 · Cited by 84
Cancer Immunoediting: From Immune Surveillance to Immune Escape
Kim, R. (2007) · Elsevier eBooks · doi:10.1016/b978-012372551-6/50066-3 · Cited by 84
Nakajima, H., Ishikawa, Y., Furuya, M., Sano, T., Ohno, Y., Horiguchi, J., & Oyama, T. (2012) · Breast Cancer · doi:10.1007/s12282-012-0354-1 · Cited by 81
McNamara, K. M., Yoda, T., Miki, Y., Chanplakorn, N., Wongwaisayawan, S., Incharoen, P., Kongdan, Y., Wang, L., Takagi, K., Takagi, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12121 · Cited by 79
Wang, Y., Overstreet, A.-M. C., Chen, M., Wang, J., Zhao, H., Ho, P.-C., Smith, M. A., & Wang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3441 · Cited by 78
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Cerbelli, B., Pernazza, A., Botticelli, A., Fortunato, L., Monti, M., Sciattella, P., Campagna, D., Mazzuca, F., Mauri, M., Naso, G., et al. (2017) · BioMed Research International · doi:10.1155/2017/1750925 · Cited by 72
Regulators and mechanisms of anoikis in triple-negative breast cancer (TNBC): A review
Tajbakhsh, A., Rivandi, M., Abedini, S., Pasdar, A., & Sahebkar, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.009 · Cited by 72
EGFR expression and gene copy number in triple-negative breast carcinoma
Gümüşkaya, B., Alper, M., Hücümenoğlu, S., Altundağ, K., Üner, A., & Güler, G. (2010) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2010.07.118 · Cited by 70
Kim, J., Park, K., Jung, H. H., Lee, E., Cho, E. Y., Lee, K. H., Bae, S. Y., Lee, S. K., Kim, S. W., Lee, J. E., et al. (2016) · Cancer Research and Treatment · doi:10.4143/crt.2015.430 · Cited by 70
Shi, F., Xiao, F., Ding, P., Qin, H., & Huang, R. (2016) · Archives of Medical Research · doi:10.1016/j.arcmed.2016.11.001 · Cited by 68
Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer
Iqbal, S., Vishnubhatla, S., Raina, V., Sharma, S., Gogia, A., Deo, S., Mathur, S. R., & Shukla, N. K. (2015) · SpringerPlus · doi:10.1186/s40064-015-1071-y · Cited by 67
İnanç, M., Özkan, M., Karaca, H., Berk, V., Bozkurt, O., Duran, A. O., Özaslan, E., Akgün, H., Tekelioğlu, F., & Elmalı, F. (2013) · Medical Oncology · doi:10.1007/s12032-013-0801-7 · Cited by 64
Prognostic and predictive value of Ki-67 in triple-negative breast cancer
Wang, W., Wu, J., Zhang, P., Fei, X., Zong, Y., Chen, X., Huang, O., He, J., Chen, W., Li, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9075 · Cited by 62
Jansson, S., Bendahl, P., Grabau, D. A., Falck, A., Fernö, M., Aaltonen, K. E., & Rydén, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102176 · Cited by 61
Mathe, A., Wong‐Brown, M. W., Locke, W. J., Stirzaker, C., Braye, S. G., Forbes, J., Clark, S. J., Avery‐Kiejda, K. A., & Scott, R. J. (2016) · Scientific Reports · doi:10.1038/srep33435 · Cited by 57
Hilborn, E., Gacic, J., Fornander, T., Nordenskjöld, B. A., Stål, O., & Jansson, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.464 · Cited by 53
The Functional Role of Notch Signaling in Triple-Negative Breast Cancer
Speiser, J. J., Erşahin, Ç. H., & Osipo, C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00013-7 · Cited by 51
Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.
Nakagawa, M., Bando, Y., Nagao, T., Morimoto, M., Takai, C., Ohnishi, T., Honda, J., Moriya, T., Izumi, K., Takahashi, M., et al. (2011) · PubMed · Cited by 43
Hashmi, A. A., Naz, S., Hashmi, S. K., Hussain, Z. F., Irfan, M., Bakar, S. M. A., Faridi, N., Khan, A., & Edhi, M. M. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3477-4 · Cited by 34
Saloustros, E. S., Nikolaou, M., Kalbakis, K., Polyzos, A., Christophillakis, C. H., Kentepozidis, N. K., Pistamaltzian, N. F., Kouroussis, C., Vamvakas, L., Georgoulias, V., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.10.013 · Cited by 25
Liu, Y., Wang, K., Hua, X., Zhai, X.-J., Wang, L., & Wang, W. (2016) · Oncology Letters · doi:10.3892/ol.2016.4778 · Cited by 23
Long non-coding RNAs as novel biomarkers for breast cancer invasion and metastasis
Zhang, K., Luo, Z., Zhang, Y., Song, X., Zhang, L., Wu, L., & Liu, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6462 · Cited by 19
Luo, Y., Huang, W., Zhang, H., & Liu, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8104 · Cited by 19
Chu, Q. D., King, T. A., & Hurd, T. C. (2012) · International Journal of Breast Cancer · doi:10.1155/2012/671684 · Cited by 16
Ilie, S. M., Bacinschi, X. E., Botnariuc, I., & Anghel, R. M. (2018) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s175556 · Cited by 16
Long noncoding RNA LINP1: scaffolding non-homologous end joining
Sakthianandeswaren, A., Liu, S., & Sieber, O. M. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.59 · Cited by 15
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Metadata
- Authors
- da Silva, J. L., Cardoso Nunes, N. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 145
- Pages
- 102855
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2995652422
- Cited by
- 270
- References
- 123
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.